{"preliminary_commentary":{"by_channel":{"x_thread":30,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02891161\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["durvalumab","radiation therapy"]],"indication":"localized urothelial cancer of bladder","name":"DUART","nct_id":"NCT02891161","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=duart-nct02891161. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DUART","arms":[{"description":"Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.","label":"Arm A: Safety Run In Phase Ib","type":"EXPERIMENTAL"},{"description":"Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2.. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Adjuvant durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.","label":"Arm B: Investigational Treatment Phase II","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2022-04-27","type":"ACTUAL"},"conditions":["Urothelial Cancer"],"enrollment":{"count":26,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"durvalumab","otherNames":[],"type":"DRUG"},{"name":"Radiation Therapy","otherNames":["RT"],"type":"RADIATION"}],"last_update":"2024-11-27","lead_sponsor":"Monika Joshi, MD","official_title":"Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: Big Ten Cancer Research Consortium BTCRC-GU15-023","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2019-08-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"Phase Ib: Safety Assessment - Evaluation of DLT (Dose Limiting Toxicity) Rate","timeFrame":"Begin W1 and every 2 chemotherapy cycles (2 weeks) thereafter, for up to 2 years or until unacceptable toxicity."},{"measure":"All Phases: Progression Free Survival Rate at 1 Year","timeFrame":"From C1D1 to Progression or until death for 1 year"},{"measure":"Phase II: Disease Control Rate to Concurrent durvaRT Followed by Durvalumab","timeFrame":"From C1D1 until death or up to a maximum of 39 months."}],"references":[{"citation":"Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekhoo H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y. Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. J Immunother Cancer. 2023 Feb;11(2):e006551. doi: 10.1136/jitc-2022-006551.","pmid":"36822667","type":"DERIVED"}],"start_date":{"date":"2016-11-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder","url":"https://clinicaltrials.gov/study/NCT02891161"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/duart-nct02891161"}